Division of Stroke and Critical Care CUMC NINY
WARCEF: Warfarin Aspirin Reduced Cardiac Ejection Fraction Study


 

WARCEF is a study for people who have poor heart function (heart failure). Having poor heart function increases the risk that a person may have a stroke. The purpose of this research study is to determine which of two commonly used treatments, warfarin (Coumadin), or aspirin is better for preventing death and stroke in patients with poor heart function. Warfarin inhibits the clotting of blood while aspirin inhibits the clumping of platelets in the blood that form clots.

Eligible Participants will have: (1) Cardiac ejection fraction of 30% or less;
(2) Stroke within the past 3 months

Participation Includes: Study medication, neurological and cardiac exam, blood tests

©2004-2006 The Neurological Institute of New York • Affiliated with New York-Presbyterian Hospital
• Columbia University Medical Center • Division of Stroke and Critical Care • 710 W 168th St, New York, NY 10032
Updated September 6, 2006
Comments